BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20203415)

  • 1. Stromal thrombospondin-1 expression is a prognostic indicator and a new marker of invasiveness in intraductal papillary-mucinous neoplasm of the pancreas.
    Okada K; Hirabayashi K; Imaizumi T; Matsuyama M; Yazawa N; Dowaki S; Tobita K; Ohtani Y; Tanaka M; Inokuchi S; Makuuchi H
    Biomed Res; 2010 Feb; 31(1):13-9. PubMed ID: 20203415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary-mucinous neoplasms.
    Nara S; Shimada K; Kosuge T; Kanai Y; Hiraoka N
    Am J Surg Pathol; 2008 Feb; 32(2):243-55. PubMed ID: 18223327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of pathologic subtypes and minimal invasion in intraductal papillary mucinous neoplasms of the pancreas.
    Kim J; Jang KT; Mo Park S; Lim SW; Kim JH; Lee KH; Lee JK; Heo JS; Choi SH; Choi DW; Rhee JC; Lee KT
    Tumour Biol; 2011 Jun; 32(3):535-42. PubMed ID: 21190101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases.
    Nara S; Onaya H; Hiraoka N; Shimada K; Sano T; Sakamoto Y; Esaki M; Kosuge T
    Pancreas; 2009 Jan; 38(1):8-16. PubMed ID: 18665010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of KL-6 in the subtyping of intraductal papillary mucinous neoplasia of the pancreas, including carcinoma, dysplasia, and hyperplasia.
    Ohtsuki Y; Watanabe R; Kimura M; Nomura K; Maeda T; Kito K; Takeji M; Lee GH; Furihata M
    Med Mol Morphol; 2015 Jun; 48(2):85-91. PubMed ID: 24908068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
    Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
    Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas.
    Adsay NV; Merati K; Basturk O; Iacobuzio-Donahue C; Levi E; Cheng JD; Sarkar FH; Hruban RH; Klimstra DS
    Am J Surg Pathol; 2004 Jul; 28(7):839-48. PubMed ID: 15223952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
    Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
    Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the tumor suppressor gene maspin and its significance in intraductal papillary mucinous neoplasms of the pancreas.
    Kashima K; Ohike N; Mukai S; Sato M; Takahashi M; Morohoshi T
    Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):86-90. PubMed ID: 18234645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of subtypes of biliary intraductal papillary mucinous neoplasm and their MUC1, MUC2, and DPC4 expression patterns differ from pancreatic intraductal papillary mucinous neoplasm.
    Sclabas GM; Barton JG; Smyrk TC; Barrett DA; Khan S; Kendrick ML; Reid-Lombardo KM; Donohue JH; Nagorney DM; Que FG
    J Am Coll Surg; 2012 Jan; 214(1):27-32. PubMed ID: 22112419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct patterns of peritumoral histological findings in subtypes of intraductal papillary mucinous neoplasms of the pancreas.
    Saito M; Imada H; Suzuki T; Sata N; Yasuda Y; Maetani I; Fukushima N
    Ann Diagn Pathol; 2015 Oct; 19(5):347-52. PubMed ID: 26265194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of CD117, CK17, CK20, MUC4, villin and mismatch repair deficiency in pancreatic intraductal papillary mucinous neoplasm.
    Detlefsen S; Jakobsen M; Nielsen MFB; Klöppel G; Mortensen MB
    Pathol Res Pract; 2021 Jan; 217():153312. PubMed ID: 33341087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcellular localization of KL-6 mucin in intraductal papillary mucinous neoplasm of the pancreas.
    Inagaki Y; Seyama Y; Hasegawa K; Tang W; Kokudo N
    Drug Discov Ther; 2014 Aug; 8(4):173-7. PubMed ID: 25047009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas.
    Basturk O; Chung SM; Hruban RH; Adsay NV; Askan G; Iacobuzio-Donahue C; Balci S; Zee SY; Memis B; Shia J; Klimstra DS
    Virchows Arch; 2016 Nov; 469(5):523-532. PubMed ID: 27591765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implication of morphological subtypes in management of intraductal papillary mucinous neoplasm.
    Yamada S; Fujii T; Shimoyama Y; Kanda M; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Nakao A; Kodera Y
    Ann Surg Oncol; 2014 Jul; 21(7):2444-52. PubMed ID: 24562937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Added value of diffusion-weighted imaging to MR cholangiopancreatography with unenhanced mr imaging for predicting malignancy or invasiveness of intraductal papillary mucinous neoplasm of the pancreas.
    Kang KM; Lee JM; Shin CI; Baek JH; Kim SH; Yoon JH; Han JK; Choi BI
    J Magn Reson Imaging; 2013 Sep; 38(3):555-63. PubMed ID: 23390008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive carcinoma derived from intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic and immunohistochemical study of eight cases.
    Fukushima N; Mukai K; Sakamoto M; Hasebe T; Shimada K; Kosuge T; Kinoshita T; Hirohashi S
    Virchows Arch; 2001 Jul; 439(1):6-13. PubMed ID: 11499841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.